

# Evelyne SÃ©gal-Bendirdjian

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2305011/publications.pdf>

Version: 2024-02-01

56  
papers

2,063  
citations

257101

24  
h-index

243296

44  
g-index

59  
all docs

59  
docs citations

59  
times ranked

5432  
citing authors

#	ARTICLE	IF	CITATIONS
1	Exploring <i>hTERT</i> promoter methylation in cutaneous Tâ€cell lymphomas. <i>Molecular Oncology</i> , 2022, 16, 1931-1946.	2.1	12
2	<i>hTERT</i> DNA Methylation Analysis Identifies a Biomarker for Retinoic Acid-Induced <i>hTERT</i> Repression in Breast Cancer Cell Lines. <i>Biomedicines</i> , 2022, 10, 695.	1.4	2
3	Complex context relationships between DNA methylation and accessibility, histone marks, and <i>hTERT</i> gene expression in acute promyelocytic leukemia cells: perspectives for allâ€trans retinoic acid in cancer therapy. <i>Molecular Oncology</i> , 2020, 14, 1310-1326.	2.1	7
4	The long non coding RNA H19 as a biomarker for breast cancer diagnosis in Lebanese women. <i>Scientific Reports</i> , 2020, 10, 22228.	1.6	16
5	<i>hMZF-2</i> , the Elusive Transcription Factor. <i>Frontiers in Genetics</i> , 2020, 11, 581115.	1.1	1
6	The epigenetic regulator <i>RINF</i> ( <i>CXXC5</i> ) maintains <i>SMAD7</i> expression in human immature erythroid cells and sustains red blood cells expansion.. <i>Haematologica</i> , 2020, Online ahead of print, 0-0.	1.7	2
7	Cisplatin increases <i>PD-L1</i> expression and optimizes immune check-point blockade in non-small cell lung cancer. <i>Cancer Letters</i> , 2019, 464, 5-14.	3.2	148
8	Non-canonical Roles of Telomerase: Unraveling the Imbroglio. <i>Frontiers in Cell and Developmental Biology</i> , 2019, 7, 332.	1.8	64
9	Modulation of lung cancer cell plasticity and heterogeneity with the restoration of cisplatin sensitivity by neurotensin antibody. <i>Cancer Letters</i> , 2019, 444, 147-161.	3.2	13
10	Telomerase regulation by the long non-coding RNA H19 in human acute promyelocytic leukemia cells. <i>Molecular Cancer</i> , 2018, 17, 85.	7.9	27
11	Platinum Complexes Can Bind to Telomeres by Coordination. <i>International Journal of Molecular Sciences</i> , 2018, 19, 1951.	1.8	5
12	Exploring the mechanism of inhibition of human telomerase by cysteineâ€reactive compounds. <i>FEBS Letters</i> , 2017, 591, 863-874.	1.3	5
13	Neurotensin regulation induces overexpression and activation of <i>EGFR</i> in HCC and restores response to erlotinib and sorafenib. <i>Cancer Letters</i> , 2017, 388, 73-84.	3.2	27
14	Neurotensin Receptor 1 Antagonist SR48692 Improves Response to Carboplatin by Enhancing Apoptosis and Inhibiting Drug Efflux in Ovarian Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 6516-6528.	3.2	18
15	Association of a Platinum Complex to a G-Quadruplex Ligand Enhances Telomere Disruption. <i>Chemical Research in Toxicology</i> , 2017, 30, 1629-1640.	1.7	13
16	Heparan Sulfate Proteoglycans Promote Telomerase Internalization and MHC Class II Presentation on Dendritic Cells. <i>Journal of Immunology</i> , 2016, 197, 1597-1608.	0.4	16
17	<i>WT1</i> expression is inversely correlated with <i>MYCN</i> amplification or expression and associated with poor survival in nonâ€ <i>MYCN</i> â€amplified neuroblastoma. <i>Molecular Oncology</i> , 2016, 10, 240-252.	2.1	9
18	A preclinical mouse model of glioma with an alternative mechanism of telomere maintenance (ALT). <i>International Journal of Cancer</i> , 2015, 136, 1546-1558.	2.3	23

#	ARTICLE	IF	CITATIONS
19	Identification of human telomerase assembly inhibitors enabled by a novel method to produce hTERT. <i>Nucleic Acids Research</i> , 2015, 43, e99-e99.	6.5	12
20	cAMP-Dependent Protein Kinase A (PKA)-Mediated c-Myc Degradation Is Dependent on the Relative Proportion of PKA-I and PKA-II Isozymes. <i>Molecular Pharmacology</i> , 2015, 88, 469-476.	1.0	3
21	Pro-survival role of p62 during granulocytic differentiation of acute myeloid leukemia cells. <i>Molecular and Cellular Oncology</i> , 2014, 1, e970066.	0.3	8
22	p62/SQSTM1 upregulation constitutes a survival mechanism that occurs during granulocytic differentiation of acute myeloid leukemia cells. <i>Cell Death and Differentiation</i> , 2014, 21, 1852-1861.	5.0	53
23	Antitumor <i>trans</i> -N-Heterocyclic Carbene-amine-Pt(II) Complexes: Synthesis of Dinuclear Species and Exploratory Investigations of DNA Binding and Cytotoxicity Mechanisms. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 2074-2086.	2.9	72
24	Activation of Both Protein Kinase A (PKA) Type I and PKA Type II Isozymes Is Required for Retinoid-Induced Maturation of Acute Promyelocytic Leukemia Cells. <i>Molecular Pharmacology</i> , 2013, 83, 1057-1065.	1.0	14
25	Cyclic AMP can promote APL progression and protect myeloid leukemia cells against anthracycline-induced apoptosis. <i>Cell Death and Disease</i> , 2013, 4, e516-e516.	2.7	29
26	Loss of the Malignant Phenotype of Human Neuroblastoma Cells by a Catalytically Inactive Dominant-Negative hTERT Mutant. <i>Molecular Cancer Therapeutics</i> , 2012, 11, 2384-2393.	1.9	15
27	cFos Mediates cAMP-Dependent Generation of ROS and Rescue of Maturation Program in Retinoid-Resistant Acute Promyelocytic Leukemia Cell Line NB4-LR1. <i>PLoS ONE</i> , 2012, 7, e50408.	1.1	3
28	hTERT Promotes Imatinib Resistance in Chronic Myeloid Leukemia Cells: Therapeutic Implications. <i>Molecular Cancer Therapeutics</i> , 2011, 10, 711-719.	1.9	24
29	Epigenetic plasticity of hTERT gene promoter determines retinoid capacity to repress telomerase in maturation-resistant acute promyelocytic leukemia cells. <i>Leukemia</i> , 2010, 24, 613-622.	3.3	27
30	The telomere story or the triumph of an open-minded research. <i>Biochimie</i> , 2010, 92, 321-326.	1.3	19
31	Telomerase regulation in hematological cancers: A matter of stemness?. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2009, 1792, 229-239.	1.8	25
32	Functional involvement of RINF, retinoid-inducible nuclear factor (CXXC5), in normal and tumoral human myelopoiesis. <i>Blood</i> , 2009, 113, 3172-3181.	0.6	47
33	Telomeres and telomerase: From basic research to clinical applications. <i>Biochimie</i> , 2008, 90, 1-4.	1.3	16
34	Telomerase targeting by retinoids in cells from patients with myeloid leukemias of various subtypes, not only APL. <i>Leukemia</i> , 2006, 20, 599-603.	3.3	18
35	Diagnostics, Prognostic and Therapeutic Exploitation of Telomeres and Telomerase in Leukemias. <i>Current Pharmaceutical Biotechnology</i> , 2006, 7, 171-183.	0.9	10
36	Telomeres and Telomerase: Pharmacological Targets for New Anticancer Strategies?. <i>Current Cancer Drug Targets</i> , 2006, 6, 147-180.	0.8	66

#	ARTICLE	IF	CITATIONS
37	Immunodetection of human telomerase reverse-transcriptase (hTERT) re-appraised: nucleolin and telomerase cross paths. <i>Journal of Cell Science</i> , 2006, 119, 2797-2806.	1.2	112
38	Retinoid/arsenic combination therapy of promyelocytic leukemia: induction of telomerase-dependent cell death. <i>Leukemia</i> , 2005, 19, 1806-1811.	3.3	38
39	Inhibition of human telomerase by oligonucleotide chimeras, composed of an antisense moiety and a chemically modified homo-oligonucleotide. <i>FEBS Letters</i> , 2005, 579, 1411-1416.	1.3	18
40	Death receptor signaling regulatory function for telomerase: hTERT abolishes TRAIL-induced apoptosis, independently of telomere maintenance. <i>Oncogene</i> , 2004, 23, 7469-7474.	2.6	76
41	Retinoic acid receptor $\beta$ and retinoid-X receptor-specific agonists synergistically target telomerase expression and induce tumor cell death. <i>Oncogene</i> , 2003, 22, 9142-9150.	2.6	40
42	Apoptosome-independent Pathway for Apoptosis. <i>Journal of Biological Chemistry</i> , 2003, 278, 29571-29580.	1.6	34
43	Staurosporine induces apoptosis through both caspase-dependent and caspase-independent mechanisms. <i>Oncogene</i> , 2001, 20, 3354-3362.	2.6	366
44	Orchestration of multiple arrays of signal cross-talk and combinatorial interactions for maturation and cell death: another vision of t(15;17) preleukemic blast and APL-cell maturation. <i>Oncogene</i> , 2001, 20, 7161-7177.	2.6	32
45	Retinoids down-regulate telomerase and telomere length in a pathway distinct from leukemia cell differentiation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2001, 98, 6662-6667.	3.3	90
46	Autonomous Retinoid Death Signaling Is Suppressed by Converging Signaling Pathways in Immature Leukemia Cells. <i>Molecular Endocrinology</i> , 2001, 15, 1154-1169.	3.7	49
47	Ectopic expression of Bcl-2 switches over nuclear signalling for cAMP-induced apoptosis to granulocytic differentiation. <i>Cell Death and Differentiation</i> , 2000, 7, 1081-1089.	5.0	21
48	Nuclear Translocation of a Leukocyte Elastase Inhibitor/Elastase Complex during Staurosporine-Induced Apoptosis: Role in the Generation of Nuclear L-DNase II Activity. <i>Experimental Cell Research</i> , 2000, 254, 99-109.	1.2	63
49	Alteration in p53 pathway and defect in apoptosis contribute independently to cisplatin-resistance. <i>Cell Death and Differentiation</i> , 1998, 5, 390-400.	5.0	18
50	Isolation of Mitochondrial DNA-less Mouse Cell Lines and Their Application for Trapping Mouse Synaptosomal Mitochondrial DNA with Deletion Mutations. <i>Journal of Biological Chemistry</i> , 1997, 272, 15510-15515.	1.6	64
51	Isolation and Characterization of Mitochondrial DNA-less Lines from Various Mammalian Cell Lines by Application of an Anticancer Drug, Ditercalinium. <i>Biochemical and Biophysical Research Communications</i> , 1997, 239, 257-260.	1.0	48
52	Cisplatin Resistance in a Murine Leukemia Cell Line Is Associated with a Defective Apoptotic Process. <i>Experimental Cell Research</i> , 1995, 218, 201-212.	1.2	60
53	Inhibition of DNA topoisomerases I and II and induction of apoptosis by erbstatin and tyrphostin derivatives. <i>Biochemical Pharmacology</i> , 1994, 48, 549-560.	2.0	29
54	Evidence for a reverse transcription intermediate for a marked line transposon in tumoral rat cells. <i>Biochemical and Biophysical Research Communications</i> , 1991, 181, 863-870.	1.0	21

#	ARTICLE	IF	CITATIONS
55	Selective alteration of mitochondrial function by ditercalinium (NSC 335153), a DNA bisintercalating agent. <i>Biochemical Pharmacology</i> , 1990, 39, 109-122.	2.0	11
56	Telomeres and Telomerase in Neuroblastoma. , 0, , .		1